족과관절염좌 환자에 대한 동씨침법과 일반침법의 효과에 대한 비교 연구

안호진,정동화,황규선,윤기붕,김태우,문장혁,백종엽,이상무,Ahn, Ho-jin,Jeong, Dong-hwa,Hwang, Kyu-seon,Yoon, Ki-bung,Kim, Tae-woo,Moon, Jang-huyk,Baek, Jong-yeob,Lee, Sang-moo 대한침구의학회 2003 대한침구의학회지 Vol.20 No.1

Objective: The purpose of this study is to compare the effects of Dong-si acupuncture therapy and General acupuncture therapy for the patients with acute ankle sprain. Methods : This study has been carried out for 60 cases of ankle sprain patients who have visited Dong-Seo Oriental medical Hospital from May 1, 2002 to September 30, 2002. We have treated 30 cases of them by Dong-si acupuncture therapy and the other 30 cases by General acupuncture therapy. And we have compared those two group. Results : 1. There was no significant difference at the treatment period and the number of treatment times in comparing two groups. 2. The number of treatment times for good effect is that : Dong-si took $1.57{\pm}0.85$ times and General acupuncture therapy took $2.15{\pm}0.96$ times. And we have found that the effect of Dong-si acupuncture therapy is faster than the other.

이영훈의 노랫말에 나타난 유동적(流動的) 풍격미

안시현(Ahn, Si-hyeon),김동문(Kim, Dong-moon) 한국문화융합학회 2018 문화와 융합 Vol.40 No.5

1980년 중반에 나타난 이문세의 발라드는 이문세만의 감성을 살리어 새로운 팝 발라드를 형성함으로써 ‘팝 발라드의 원조’로 불리었다. 그것은 이영훈이란 작가와 이문세라는 가수의 콤비가 만났기 때문에 가능한 것이다. 따라서 이문세의 노래를 아름답게 만들어준 이영훈이라는 작가에 대한 심미의식을 고찰하는데 연구의 목적을 두고 고찰하였다. 연구방법은 이영훈의 생애를 살펴보고, 1985~1988년 사이의 작품 중 이문세가 노래하고 이영훈이 작사, 작곡한 곡 중 시간적 흐름이 표현된 작품을 구체적으로 분석하여, 동양적 관점에서 문학의 대표적 미학범주인 당나라 사공도(司空圖)의 이십사시품(二十四詩品) 중 유동(流動)의 미학범주를 적용하여 탐색하였다. 대중음악평론가 박준흠은 이영훈과 이문세를 일컬어 “1980년대 주류음악 신 최상의 작품 생산 콤비”라고 하였다. 그는 왜 ‘신’이란 관형사를 붙였을까에 대한 의문을 갖고 이영훈의 작품내용을 분석한 결과 사랑과 이별에 대한 내면의 심상을 시간적 흐름에 맞추어 표현함으로써 멈춤이 아닌 지속성을 유추할 수 있었고, 이를 살아 움직이는 생명의 유동적 풍격미로 정의하였다. 무엇보다 이영훈의 시를 이문세가 80년대 이전의 트로트와는 달리 지성, 이성, 감성이 혼융된 ‘발라드풍’으로 노래함으로써 ‘발라드의 원조’로 평가 받게 되면서 ‘신’이란 단어가 붙여 진 듯하다. In the mid-1980s, a songwriter, Lee Young-hoon, and singer, Lee Moon-sae was called as a pioneer of pop ballads. Even though ir is very difficult for a singer to always perform in a new way, Lee Moon- sae gave new performance all the time. This may have been possible due to Lee Young-hoon who beautifully wrote songs for Lee Moon-sae, and therefore, this article aimed to study the aesthetic sense of Lee Young-hoon. The article analyzed the life of Lee Young-hoon and his 4 representative songs, and apply an aesthetic category of flow among Twenty-four Poems made by Sagongdo in the Chinese Tang Dynasty. A pop music critic, Park Joon-heum referred Lee Young-hoon and Lee Moon-sae as “a duo to produce the best songs, a god of mainstream music in the 1980s.” To answer a question why he called them a ‘god’, Lee Young-hoon’s songs were closely analyzed. As a result, it can be inferred that the songs symbolize continuity of the narrator s mind, by expressing intrinsic images of love and style of the vigorous movement of life. Above all, unlike Korean trot prior to the 1980s, Lee Moon-sae sung Lee Young-hoon’s lyrics in ‘a ballad style’ that combined intelligence and rationality with sensitivity, giving him a title, ‘a pioneer of ballad’. This may have named them as a ‘god’.

Korea Pathfinder Lunar Orbiter (KPLO) Operation: From Design to Initial Results

Moon-Jin Jeon,Young-Ho Cho,김은혁,Dong-Gyu Kim,Young-Joo Song,홍승범,Jonghee Bae,Jun Bang,Jo Ryeong Yim,Dae-Kwan Kim 한국우주과학회 2024 Journal of Astronomy and Space Sciences Vol.41 No.1

Korea Pathfinder Lunar Orbiter (KPLO) is South Korea’s first space exploration mission, developed by the Korea Aerospace Research Institute. It aims to develop technologies for lunar exploration, explore lunar science, and test new technologies. KPLO was launched on August 5, 2022, by a Falcon-9 launch vehicle from cape canaveral space force station (CCSFS) in the United States and placed on a ballistic lunar transfer (BLT) trajectory. A total of four trajectory correction maneuvers were performed during the approximately 4.5-month trans-lunar cruise phase to reach the Moon. Starting with the first lunar orbit insertion (LOI) maneuver on December 16, the spacecraft performed a total of three maneuvers before arriving at the lunar mission orbit, at an altitude of 100 kilometers, on December 27, 2022. After entering lunar orbit, the commissioning phase validated the operation of the mission mode, in which the payload is oriented toward the center of the Moon. After completing about one month of commissioning, normal mission operations began, and each payload successfully performed its planned mission. All of the spacecraft operations that KPLO performs from launch to normal operations were designed through the system operations design process. This includes operations that are automatically initiated post-separation from the launch vehicle, as well as those in lunar transfer orbit and lunar mission orbit. Key operational procedures such as the spacecraft’s initial checkout, trajectory correction maneuvers, LOI, and commissioning were developed during the early operation preparation phase. These procedures were executed effectively during both the early and normal operation phases. The successful execution of these operations confirms the robust verification of the system operation.

만성 신부전을 동반한 Laurence Moon-Bardet Biedl 증후군 1례

박래경,이동환,문철,김은미,Park Lae Kyong,Lee Dong Hwan,Moon Chul,Kim Eun Mi 대한소아신장학회 1998 Childhood kidney diseases Vol.2 No.2

The Laurence Moon-Bardet Biedl syndrome is characterized by obesity, mental retardation, visual impairment with retinitis pigmentosa, polydactyly, hypogonadism and renal manifestations. We experienced an 11 years old female with Laurence Moon-Baret Biedl syndrome associated chronic renal failure. She was diagnosed to have LMB syndrom according to the clinical manifestations of polydactyly on hands and feet, mental retardation, obesity, retinitis pigmentosa and chronic renal failure. She is on maintenance hemodialysis now.

Metoclopramide가 휜쥐의 血壓에 미치는 影響

임동윤,최동준,김규형,최철희,박재윤,문재규,김문석,황두환 中央醫學社 1988 中央醫學 Vol.53 No.9

Influences of metocopramide (MCP), which is a seletive dopaminergic antagonist, on blood pressure of the rat and its mechanism of action were investigated in the present study. MCP administered into a femoral vein of the rat caused markedly a dose-related fall in blood pressure followed by secondary transient pressor response. The depressor action evoked by MCP was not blocked by pretreatment of atropine or chlorisondamine, while the pressor action was inhibited significantly. Prazosin treatment reduced markedly both of depressor and pressor induced by MCP. MCP-evoked pressor action was not affected by clonidine, but the depressor response was attenuated significantly. Debrisoquin treatment made the inhibited response to MCP-induced pressor response, while did not affect the depressor action. Both of pressor and depressor responses evoked by MCP were not influenced by cyproheptadine. The hypertensive activity induced by nor epinephrine was weakened markedly by the infusion of MCP (1.50 mg/kg/30min.), but the pressor action evoked by dopamine not affected. These experimental data suggest that MCP produces biphasic responses (depressor and pressor) in blood pressure of the rat, and that the hypotensive activity is due to adrenergic alpha-receptors blockade, and that pressor activity is exerted through stimulation of cholinergic nicotinic receptors in autonmic ganglia.

딜라트렌정(카르베딜롤 25mg)에 대한 카베롤 정의 생물학적 동등성

조혜영,이문석,박순철,임동구,문재동,이용복 한국약제학회 2001 Journal of Pharmaceutical Investigation Vol.31 No.4

Carvedilol is an antihypertensive and antianginal compound that combines nonselective beta-adrenoceptor blocking and vasodilation properties and is devoid of intrinsic sympathomimetic activity. The purpose of the present study was to evaluate the bioequivalence of two carvedilol tablets, Dilatrend^TM (Chong Kun Dang Pharmaceutical Co., Ltd.) and Carvelol^TM (Dae Won Pharmaceutical Co., Ltd.), according to the prior and revised guidelines of Korea Food and Drug Administration (KFDA). The carvedilol release from the two carvedilol tablets in vitro was tested using KP VII Apparatus Ⅱ method with various different kinds of dissolution media (pH 1.2, 4.0, 6.8 buffer solution, water and blend of PSB80 into water). Eighteen normal male volunteers, 24.22±1.86 years in age and 64.81±4.56 kg in body weight, were divided into two groups and a randomized 2×2 cross-over study was employed. After one tablet containing 25 mg of carvedilol was orally administered, blood was taken at predetermined time intervals and the concentrations of carvedilol in serum were determined using HPLC method with fluorescence detector. The dissolution profiles of two carvedilol tablets were very similar at all dissolution media. Besides, the pharmacokinetic parameters such as AUC_t C_max and T_max were calculated and ANOVA test was utilized for the statistical analysis of the parameters using non-transformed and logarithmically transformed AUC_t and C_max The results showed that the differences in AUC_t C_max and T_max between two tablets based on the Dilatrend^TM were 2.23%, -2.00% and 0.00%, respectively. Minimum detectable differences (Δ) at α=0.05 and 1-β=8 were less than 20% (e.g., 13.55% and 17.61% for AUC_t and C_max respectively). The powers (1-β) at α=0.05, Δ=0.2 for AUC_t and C_max were 98.08% and 88.81%, respectively. The 90% confidence intervals were within 20% (e.g., -5.69∼10.16 and -12.30∼8.30 for AUC_t and C_max, respectively). There were no sequence effect between two tablets in logarithmically transformed AUC_t and C_max, The 90% confidence intervals using logarithmically transformed were within the acceptance range of log(0.8) to log(1.25) (e.g., 0.95∼1.11 and 0.89∼1.09 for AUC_t and C_max respectively). Two parameters met the criteria of prior and revised KFDA guideline for bioequivalence, indicating that Carvelol^TM tablet is bioequivalent to Dilatrend^TM tablet.

복강경담낭절제술에서 수술전 간담도신티그라피와 경구담낭조영술의 의의

문대혁(Dae Hyuk Moon),양승오(Seoung Oh Yang),이희경(Hee Kyung Lee),원경숙(Kyoung Sook Won),류진숙(Jin Sook Ryu),한동복(Dong Bok Han),박철민(Cheol Min Park),이문규(Moon Gyu Lee),박광민(Kwang Min Park),이승규(Sung Gyu Lee) 대한핵의학회 1997 핵의학 분자영상 Vol.31 No.1

N/A 131I-6β-iodomethyl-19-norcholesterol(NP-59) has an advantage to assess adrenal dysfunction caused by adrenal cortical disorders. The aim of this study is to evaluate the clinical usefulness of NP-59 scintigraphy in each adrenral disease. Ten patients who did eleven NP-59 adrenal scintigraphies at Dong-A University Hospital from March 1990 to December 1996 were selected as the subject. Among the subject there were 5 cases of Cushing's syndrome, 2 cases of incidentaloma, 1 case of metastatic adrenal tumor, liver cirrhosis with hirsutism and hypertension respectively. Among 5 case of Cushing's syndrome, there were 2 cases of Cushing's disease, 2 cases of adrenal adenoma and 1 case of adrenal carcinoma. There are no disagreement between clinical diagnosis and scan finding in Cushing's syndrome. In 2 incidentaloma cases, even though one is interpretated as a functioning tumor, both of 2 cases could avoid unnecessary biopsy according to scintigraphy result. One case of hirsutism, clinically adrenal originated, revealed the normal scintigraphic hirsutism was extra-adrenal origin. One case of hypertension took the study to exclude the possibility of primary aldosteronism. Normal suppression scan finding revealed that primary aldosteronism did not exist in this case. In conclusion, NP-59 scintigraphy was very useful in diagnosis and differential diagnosis of Cushing's syndrome and it could avoid unnecessary biopsy in the incidental adrenal tumor.

Modified Nance appliance를 이용한 매복치의 교정치료

문철현(Cheol-Hyun Moon),이동근(Dong-Gun Lee) 대한치과의사협회 2007 대한치과의사협회지 Vol.45 No.4

저자들은 modified Nance appliance를 이용하여 환자의 협조에 의존하지 않고 매복된 치아의 교정적인 맹출을 시행하여 양호한 결과를 얻을 수 있었다. 특히 Moon’s appliance를 이용하여 동일 악궁 내에서 약하고 정교한 지속적인 힘을 적용 할 수 있었으며, 힘의 방향을 바꾸기 위한 과정에서 장치 전체를 철거해야 하는 번거로움을 해소 할 수 있었다. Traction of impacted tooth often requires patient compliance to place elastics to surgically exposed impacted tooth. It can be very difficult and time-consuming. The aim of this article was to describe an impacted tooth tractor, Moon s appliance, which was modified from the Nance holding arch appliance. Moon s appliance eliminates patient compliance and generates a light continuous force. We achieved the desired treatment results for impacted tooth using this appliance. This new fixed appliance can be a reasonable alternative to conventional appliances.

리마틸 정(부시라민 100㎎)에 대한 부시린 정의 생물학적 동등성

조혜영,이문석,오인준,김동현,문재동,이용복 한국약제학회 2001 Journal of Pharmaceutical Investigation Vol.31 No.2

Bucillamine is a novel cysteine derivative with two free intramolecular sulfhydryl groups, and has a preventive and therapeutic effect on adjuvant arthritis, suggesting its antirheumatic action. With respect to the effect on the immune system, bucillamine-exerted such immunoregulating actions are to nomalize an excessive reduction or acceleration in immune reaction. It is useful not only in patients with early stage of rheumatoid arthritis (RA) but also in those with active RA retained for more than 10 years. The purpose of the present study was to evaluate the bioequivalence of two bucillamine tablets, Rimatil^TM (Chong Kun Dang Pharmaceutical Co., Ltd.) and Bucilin^TM (Kuhn Il Pharmaceutical Co., Ltd.), according to the guidelines of Korea Food and Drug Administration (KFDA). Eighteen normal male volunteers, 23.67±2.09 years in age and 65.03±6.73 kg in body weight, were divided into two groups and a randomized 2×2 cross-over study was employed. After three tablets containing 100 mg of bucillamine per tablet were orally administered, blood was taken at predetermined time intervals and the concentrations of bucillamine in serum were determined using GC/MS with mass selective detector. Pharmacokinetic parameters such as AUC_t, C_max, and T_max were calculated and ANOVA test was utilized for the statistical analysis of the parameters. The results showed that the differences in AUC_t, C_max and T_max between two tablets were -0.29%, -3.20% and 8.22%, respectively, when calculated against the Rimatil^TM tablet. The powers (1-β) for AUC_t and C_max were 84.31 % and 91.16%, respectively. Minimum detectable differences (Δ) at α=0.10 and 1-β=0.8 were less than 20% (e.g., 18.58% and 16.51% for AUC_t and C_max respectively). The 90% confidence intervals were within ±20% (e.g., -12.77∼12.20 for AUC_t and -14.30∼7.90 for C_max). Two parameters met the criteria of KFDA for bioequivalence, indicating that Bucilin^TM tablet is bioequivalent to Rimatil^TM tablet.

리마틸 정(부시라민 100 mg)에 대한 부시린 정의 생물학적 동등성

조혜영,이문석,오인준,김동현,문재동,이용복 전남대학교 약품개발연구소 2001 약품개발연구지 Vol.10 No.-

Bucillamine is a novel cysteine derivative with two free intramolecular sulfhydryl groups, and has a preventive and therapeutic effect on adjuvant arthritis, suggesting its antirheumatic action. With respect to the effect on the immune system, bucillamine-exerted such immunoregulating actions are to nomalize an excessive reduction or acceleration in immune reaction. It is useful not only in patients with early stage of rheumatoid arthritis (RA) but also in those with active RA retained for more than 10 years. The purpose of the present study was to evaluate the bioequivalence of two bucillamine tablets, Rimatil^TM (Chong Kun Dang Pharmaceutical Co., Ltd.) and Bucilin^TM (Kuhn Il Pharmaceutical Co., Ltd.), according to the guidelines of Korea Food and Drug Administration (KFDA). Eighteen normal male volunteers. 23.67±2.09 years in age and 65.03±6.73㎏ in body weight, were divided into two groups and a randomized 2×2 cross-over study was employed. After three tablets containing 100㎎ of bucillamine per tablet were orally administered, blood was taken at predetermined time intervals and the concentrations of bucillamine in serum were determined using GC/MS with mass selective detector. Pharmacokinetic parameters such as AUC_t, C_max and T_max were calculated and ANOVA test was utilized for the statistical analysis of the parameters. The results showed that the differences in AUC_t, C_mex and T_max between two tablets were -0.29%, -3.20% and 8.22%, respectively, when calculated against the Rimatil^TM tablet. The powers (1-β) for AUC_t and C_max were 84.31% and 91.16%, respectively. Minimum detectable differences (Δ) at α=0.10 and 1-β=0.8 were less than 20% (e.g., 18.58% and 16.51% for AUC_t and C_max, respectively). The 90% confidence intervals were within ±20% (e.g., -12.77∼12.20 for AUC_t and -14.30∼7.90 for C_max). Two parameters met the criteria of KFDA for bioequivalence, indicating that Bucilin^TM tablet is bioequivalent to Rimatil^TM tablet.